SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
精壮小伙
Lv7
55
4540 积分
2020-12-21 加入
最近求助
最近应助
互助留言
Embracing cancer complexity: Hallmarks of systemic disease
8天前
已完结
Feasibility and tolerability of sintilimab plus anlotinib as the second‐line therapy for patients with advanced biliary tract cancers: An open‐label, single‐arm, phase II clinical trial
9天前
已完结
Tislelizumab combined with anlotinib and chemotherapy (XELOX) in the treatment of advanced gastric carcinoma: Preliminary results of a single-arm, open-label phase I/IIa trial (TALENT study)
10天前
已关闭
Toxicity and response criteria of the Eastern Cooperative Oncology Group
17天前
已完结
Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203)
24天前
已完结
Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients?
24天前
已完结
Apatinib is effective for treatment of advanced hepatocellular carcinoma
24天前
已完结
Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: a single‑center randomized controlled trial
24天前
已完结
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
24天前
已完结
Efficacy and safety of apatinib combined with transarterial chemoembolization for hepatocellular carcinoma with portal venous tumor thrombus: a retrospective study
24天前
已完结
没有进行任何应助
摘要内容,提示关闭【积分已退回】
10天前
感谢,点赞,速度真快,帮大忙了,么么哒
24天前
感谢,点赞,速度真快,帮大忙了,么么哒
1个月前
感谢,点赞,速度真快,帮大忙了,么么哒
3个月前
感谢,点赞,速度真快,帮大忙了,么么哒
3个月前
感谢,速度真快,速度真快,帮大忙了,么么哒
6个月前
感谢,点赞,速度真快,帮大忙了,么么哒
6个月前
感谢,点赞,速度真快,帮大忙了,么么哒
7个月前
感谢,点赞,速度真快,帮大忙了,么么哒
8个月前
感谢,点赞,速度真快,帮大忙了,么么哒
8个月前
最近帖子
最近评论
没有发布任何帖子
跟editor讲一下就好了,不要有心理压力
1年前
缺钱工作,单纯喜欢科研读博,虽然都累,读博相对思想自由点
1年前